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Abstract
Plants are an invaluable source of potential new anti-cancer drugs. Here, we investigated the cytotoxic activity of the
acetonic extract of Buxus sempervirens on five breast cancer cell lines, MCF7, MCF10CA1a and T47D, three aggressive triple
positive breast cancer cell lines, and BT-20 and MDA-MB-435, which are triple negative breast cancer cell lines. As a control,
MCF10A, a spontaneously immortalized but non-tumoral cell line has been used. The acetonic extract of Buxus sempervirens
showed cytotoxic activity towards all the five studied breast cancer cell lines with an IC50 ranging from 7.74 mg/ml to
12.5 mg/ml. Most importantly, the plant extract was less toxic towards MCF10A with an IC50 of 19.24 mg/ml. Fluorescence-
activated cell sorting (FACS) analysis showed that the plant extract induced cell death and cell cycle arrest in G0/G1 phase in
MCF7, T47D, MCF10CA1a and BT-20 cell lines, concomitant to cyclin D1 downregulation. Application of MCF7 and
MCF10CA1a respective IC50 did not show such effects on the control cell line MCF10A. Propidium iodide/Annexin V double
staining revealed a pre-apoptotic cell population with extract-treated MCF10CA1a, T47D and BT-20 cells. Transmission
electron microscopy analyses indicated the occurrence of autophagy in MCF7 and MCF10CA1a cell lines. Immunofluo-
rescence and Western blot assays confirmed the processing of microtubule-associated protein LC3 in the treated cancer
cells. Moreover, we have demonstrated the upregulation of Beclin-1 in these cell lines and downregulation of Survivin and
p21. Also, Caspase-3 detection in treated BT-20 and T47D confirmed the occurrence of apoptosis in these cells. Our findings
indicate that Buxus sempervirens extract exhibit promising anti-cancer activity by triggering both autophagic cell death and
apoptosis, suggesting that this plant may contain potential anti-cancer agents for single or combinatory cancer therapy
against breast cancer.
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Introduction
Breast cancer, a major worldwide health issue, is considered as
the most common malignancy and the most common cause of
cancer-related death in Western countries [1]. Standard cancer
therapy generally combines surgery, multi-therapeutic agents and
ionizing radiation [2]. These anticancer agents induce cell cycle
arrest and/or cell death by apoptotic or non-apoptotic mecha-
nisms including necrosis, senescence, autophagy and mitotic
catastrophe [3,4].
Major issues concerning conventional anticancer chemotherapy
are the occurrence of side effects induced by the non-specific
targeting of both normal and cancer cells [5,6], and the emergence
of drug-resistant cancer cells [7]. Based on this, there has been
growing interest in the use of naturally occurring molecules with
chemo-preventive and chemotherapeutic properties in cancer
treatment [8–12]. Natural products will thus continue to play
major role as active substances, model molecules for the discovery
and validation of drug targets [13,14]. Among natural sources,
plants have played an important role as a source of effective
anticancer agents [15–17]. Four examples are well known: TaxolH
from Taxus brevifolia L., vinca alkaloids from Catharanthus roseus G.
Don, camptothecin from Camptotheca acuminata, Decne and
podophyllotoxin from Podophyllum peltuturn L. [18,19].
In folk medicine, Buxus sempervirens L. is used to treat
rheumatism, arthritis, bile duct infections, diarrhea, fever and
skin ulceration. Studies highlighted the unique feature of the genus
Buxus regarding the presence of steroidal alkaloids (more than 200)
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24537[20–23]. The latter are known for exhibiting promising biological
activities including anti-acetylcholine esterase [24–27], cytotoxic
[28] and immunosuppressive activities [29]. Nevertheless, to our
knowledge, no anticancer activity of Buxus sempervirens L. extracts
has been yet described.
Based on folk medicine, we investigated here the cytotoxic effect
of the acetonic extract of Buxus sempervirens L. against five breast
cancer cell lines: MCF7, MCF10CA1a, T47D, BT-20 and MDA-
MB-435 or the spontaneously immortalized cell line MCF10A as a
control. Our results showed that the Buxus extract has specific
cytotoxic effects toward cancer cell lines by mainly inducing a
decrease in cyclin D1. Interestingly, the extract induced
autophagic cell death and apoptosis in breast cancer cells tested
and a caspase 3-independent apoptosis cell death in the aggressive
MCF10CA1a cells.
Results
Buxus acetonic extracts exhibit cytotoxic properties and
induce phenotype modifications in breast cancer cells
In order to evaluate the cytotoxicity of the acetonic extract of
Buxus, an MTT assay was monitored on five breast cancer cell
lines. The MCF7, MCF10CA1a and T47D, which are aggressive
triple positive breast cancer cells, and BT-20 and MDA-MB-435
that are triple negative breast cancer cells. The extract exhibited
cytotoxic activity toward all cancer cell lines tested, displaying
reduced IC50 (,20 mg/ml) (Figure 1A). Moreover, the IC50
obtained against the control cell line MCF10A was higher
(IC50=19.24 mg/ml, Figure 1A). These results suggest a specific
cytotoxic effect mainly against breast cancer cell lines.
In order to give a better understanding of the mechanisms of
cytotoxicity in cancer cells, we decided to carry on experiments on
aggressive triple positive cancer cells: MCF7, MCF10CA1a, T47D
and the triple negative breast cancer cell line BT-20.
First, major phenotypic changes were noticed when cancer cell
lines were incubated in the presence of Buxus extract. Hence,
interestingly, the cancer cell lines treated with the same extract
(corresponding IC50 during 72 h) displayed different apoptotic cell
shapes regarding the apoptotic volume decrease (AVD) (Figure 1B
and 1C). To further test this, cytoskeleton staining (anti-a-tubulin)
was applied. Treated MCF7, T47D and BT-20 cells exhibited a
reduced round-shape cellular form before complete detachment
from cell culture dish (Figure 1B, 1D and 1E), while MCF10CA1a
cells showed a distinct and severe shrinkage (Figure 1C). These
specific shapes are well known as the AVD due to massive efflux of
K
+ and Cl
2 through their specific channels, leading to water
escape from the cytoplasm, the latter being considered as a major
hallmark of apoptotic cells [30,31].
Finally, while DMSO-treated cells showed large nuclei with
distinguishable nucleoli, we have noticed the transformation of
nuclei into a unique pyknotic mass in dramatically-injured cells
(Figure 1 B–E). On the other hand, normal MCF10A cells did not
exhibit such dramatic phenotype changes. Together, our results
suggest a cytotoxic activity of the Buxus extract regarding
cancerous cells via apoptotic cell death.
Acetonic extract of Buxus induces cell cycle arrest
We studied the effect of the Buxus acetonic extract on the cell
cycle of the studied breast cell lines. After 24 h incubation with
the extract, stability is generally noticed in all cell cycle sub-
populations of the control cell line MCF10A cells, with a slight
increase in sub-G1 population observed with both concentrations
applied (Figure 2C). We have also noticed a little decrease in the S-
phase sub-population (Figure 2C). Interestingly, the IC50 were
capable of triggering cell death of both cancerous cell lines. Thus,
after 24 h of treatment, the sub-G1 sub-population sharply
increased from 2.82% to 30.30% and from 7.31% to 20.64%
for MCF10CA1a and MCF7, respectively (Figure 2A, Figure S1,
S2). Concomitantly, there is a decrease in G0/G1 and S-phase
sub-populations, mainly for MCF10CA1a cells from 69.59% to
Figure 1. Cytotoxic effects of the acetonic extract of Buxus
sempervirens L. towards breast cancer MCF7 and MCF10CA1a
cells. A. IC50 determined by the dose-response curves obtained by the
MTT assay. B. C. D. and E. Different cell shapes exhibited by MCF7,
MCF10CA1a, T47D, MDA-MB-435 and BT-20, respectively, treated with
Buxus extract at their respective IC50 during 72 h. Left panel: phase
contrast images; Right panel: anti-a-tubulin fluorescence staining.
Control cells are treated with vehicle DMSO (magnification 6200). Ac
Bux: acetonic Buxus extract.
doi:10.1371/journal.pone.0024537.g001
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48 h, there is a significant increase in G0/G1 sub-population to
the detriment of S and G2/M sub-populations (Figure 2A and 2B).
Finally, we have noticed in all cancer cell lines tested that a
maximum of sub-G1 cell population is reached 24 h post-
treatment, followed by a reduction (Figure 2A and 2B for MCF7
and MCF10CA1a, respectively). Concerning T47D and BT-20
cells, despite the observation of numerous floating dead cells, no
major changes are illustrated in Sub-G1 sub-populations (Figure
S3A and S3D). This could be due to the loss of the severely-
damaged cells during washing steps. It is indeed established that
the content of DNA remaining in apoptotic cells for cytometric
analysis vary markedly depending on the extent of DNA
degradation and cell washing steps [32]. Concerning MCF7 and
MCF10CA1a, striking results were also noticed regarding the
concentrations used: with high concentrations (2 times the IC50),
there is an increase in sub-G1 population, while with low
concentrations there is a decrease in S and G2/M phases (Figure
S1A and S2A).
Concerning cell cycle markers, all cancer cells tested treated
with IC50 during 24 h and 48 h showed a noticeable decrease
in cyclin D1 expression (Figure 2D and 2E, and Figure S3 B–C
and E–F). No major changes in the expression of Rb were
noticed in treated cells, we have noticed a slight decrease in
Figure 2. The acetonic extract of Buxus induces cell cycle arrest in MCF7 and MCF10CA1a breast cancer cell lines. A. MCF7 cells were
incubated for increasing period intervals (12 h, 24 h, 36 h and 48 h) with their IC50 concentrations. The results represent means 6 SEM of three
experiments. B. MCF10CA1a cells were incubated for increasing period intervals (12 h, 24 h, 36 h and 48 h) with their IC50 concentration. The results
represent means 6 SEM of three experiments. C. MCF10A cells were incubated for the same period intervals (12 h, 24 h, 36 h and 48 h) with the IC50
of MCF7 and MCF10CA1a, respectively. The results represent means 6 SEM of three independent experiments. D. Immunoblots of total cell extracts
isolated from MCF7 treated or not with plant extract as indicated and probed with an anti-cyclin D1 antibody. GAPDH was used as a loading control.
E. Immunoblots of total cell extracts isolated from MCF10CA1a treated or not with plant extract as indicated and probed with an anti-cyclin D1
antibody. GAPDH was used as a loading control. F. Immunoblots of total cell extracts isolated from MCF10A treated or not with plant extract (IC50s of
MCF7 and MCF10CA1a concentrations) as indicated and probed with an anti-cyclin D1 antibody. a-tubulin was used as a loading control. Ac Bux:
acetonic Buxus extract.
doi:10.1371/journal.pone.0024537.g002
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(Figure 2D and 2E). Nonetheless, the IC50 of MCF7 and
MCF10CA1a applied to MCF10A showed neither of the above
effects (Figure 2C and 2F). These results indicate that the failure of
tested breast cancer cells to enter S phase is due to a decrease in
cyclin D1 induced by the Buxus acetonic extract.
Buxus acetonic extract induces autophagy in breast
cancer cells
We have next investigated the role of Buxus acetonic extract in
cell death. To this end, cells were collected after 24 h and 48 h
treatment with respective IC50, double-stained with PI and
Annexin V-FITC and analyzed by FACS (Figure 3 and Figure
S4). The kinetic of cell interaction with Annexin V revealed that
the extract acts very fast (not shown). Interestingly, there is a
discrepancy in the behavior of the breast cancer cell lines. Indeed,
while with MCF10CA1a, T47D and BT-20 we revealed a pre-
apoptotic sub-population (PI
2/Annexin V
+) (13.10% versus
25.57% after 24 h and 48 h of treatment, respectively for
MCF10CA1a as an example), that latter shifted to a late apoptotic
and/or a necrotic sub-population (PI
+/Annexin V
2 quadrant)
(Figure 3B, Figure S4 A–B). However, with MCF7 cell line, we
noticed that the cell population shifted directly to PI
+ quadrants
(dead cells) without transition by the PI
2/AnnexinV
+ (Figure 3A),
even with reduced time contact kinetics (one hour intervals, data
not shown). These findings suggested that the process of death
induced by Buxus acetonic extract differs in the cancer cell lines;
MCF10CA1a, BT-20 and T47D cells die via apoptosis pathway,
while MCF7 cell death seemed to rely mainly on autophagy.
As previously seen with PI staining, reduced cell death is
observed with MCF10A, even after 48 h of treatment, confirming
the specific effect on cancerous cell lines. Paradoxically, a more
lethal action is noticed after 24 h of incubation compared to 48 h
(Figure 3C).
According to pictures obtained with transmission electronic
microscopy, untreated MCF7 cells displayed normal characteris-
tics with, however, the presence of some auto-lysosomes/auto-
phagosomes in cell cytoplasm (Figure 4A), suggesting that even in
normal growth conditions, MCF7 cells proceed to some controlled
autophagy. Nevertheless, treated MCF7 cells with the Buxus acetonic
extract (IC50 during 72 h) showed abundant auto-lysosomes/auto-
phagosomes dispersed in the cytoplasm (Figure 4A). Hence, in the
presence of the plant extract, the phenomenon is dramatically
increased, leading to cell death without any damage to mitochondria
and cytoplasmic membrane. These observations suggested that
MCF7 death is due to autophagy rather than apoptosis. This is in
agreement with previous reports showing that MCF7 cells do not
undergo apoptosis after treatment with numerous apoptosis stimuli,
including Tamoxifen [33], or injection of supra-physiological
amounts of cytochrome C [34].
Concerning MCF10CA1a cells, pictures taken after IC50
treatment during 72 h, provided several hallmarks of apoptosis
and autophagy (Figure 5A). We noticed the presence of initial
autophagic vacuoles and degradative autophagic vacuoles, peri-
nuclear localization of mitochondria, and most importantly, some
of them were damaged.
To carry on our investigation concerning autophagy we studied
a main autophagy marker, the Microtubule associated Light
Chain 3 or LC3 protein. LC3 is the mammalian homolog of the
yeast Apg8p protein, essential for amino acid starvation-induced
autophagy [35,36]. LC3 is present in two forms in cells: LC3-I is
the cytoplasmic form, which is processed into a lipidic LC3-II
form, associated with the auto-phagosome membrane [35,36].
Therefore, we compared the LC3 distribution in Buxus acetonic
extract-treated and untreated cells (Figures 4B–C, 5B–5C,
Figure S5). In DMSO-treated cells, we noticed a homogeneous
cytoplasmic distribution of unprocessed LC3-I, while in plant
extract-treated cells (IC50/72 h), many foci are depicted, corre-
sponding to lipidic transformed LC3-II, mainly around nuclei
(Figures 4C for MCF7, 5C for MCF10CA1a, Figure S5 A
for T47D and C for BT-20). This specific signal corresponds
to the auto-phagosome trans-membrane processed version of
LC3. These results are in agreement with images taken with
transmission electron microscopy (Figures 4A and 4B for MCF7
and MCF10CA1a respectively), where we noticed accumulation of
late auto-phagosomes mainly around cell nuclei. In the case of
MCF10CA1a cells, the foci pattern of LC3-II was difficult to
confirm since there was very little cytoplasm around nuclei
(Figure 5C).
Concerning immunoblots, the presence of LC3-II in untreated
(24 h) MCF7 cells, demonstrated the occurrence of controlled-
autophagy in normal cells, as already seen with transmission
electron microscopy (Figure 4A). For MCF10CA1a aggressive
cells, we found a decrease in LC3-II in Buxus acetonic extract-
treated cells (Figure 5C). This is probably because LC3-II is
present both on inner and outer auto-phagosome membranes,
with the former being degraded inside auto-lysosomes, whereas
LC3 on the outer membrane is deconjugated by Atg4 (Autophagy
related gene 4) and returns to the cytosol [35]. Finally, concerning
the control cell line MCF10A, a faint LC3-II signal is detected
when the cells were treated with the IC50 of MCF7 (Figure S6).
Immunoblots of total cell extracts from treated and non-treated
T47D and BT-20 confirmed also autophagy processing since we
have noticed the processed form of LC3 (LC3 II, 24 h and 48 h
after treatment) (Figure S5 B and D for T47D and BT-20,
respectively).
Acetonic Buxus extract induces caspase 3-independent
apoptosis in MCF10C1a
In order to get more insights on the pattern of cell death, mainly
in MCF10CA1a, we studied the activation of several additional
markers related to apoptosis by immunoblot (Figure 6A). Pro-
caspase 3 is undetectable in MCF-7 cells due to a 47-bp deletion
within exon 3 of the procaspase-3 gene that alters the reading
frame of the message, resulting in an unstable truncated
polypeptide [34,37]. According to that, activated caspase 3 was
assessed in MCF10CA1a (Figure 6A), as well as in the control cell
line MCF10A (Figure S6). Surprisingly, active caspase 3 was
absent after treatment with the plant extract, even with reduced
incubation times (Figure 6A). This result is in contradiction with
our previous finding concerning Annexin V staining; the
aggressive cell line MCF10CA1a displayed PI
2/Annexin V
+
pattern after plant treatment, illustrating an apoptotic cell death
concomitant to autophagy. Taken together, these results indicate
that MCF10CA1a death can be related only to autophagy,
triggered by metabolic stress created by damaged mitochondria
that caused an energy-deprivation state, or the autophagy is
coupled to an apoptosis cell death independent of caspase 3
activation, since we noticed occurrence of DNA damages related
apoptosis (presence of cleaved PARP and cH2AX, Figure 6A).
As the cells displayed a G1-phase arrest, we were interested in
testing levels of p21, a potent cell cycle inhibitor through
inactivation of G1-phase cyclin/CDK complexes. Surprisingly,
we have found a decrease in p21 levels in cancer cell lines tested
(Figures 4B and 5B, Figure S5 B and D). In addition, the cells
showed reduced levels of Survivin after plant extract treatment. In
the control cell line MCF10A, Survivin was detected at 24 h but
no effect on its levels is noticed after plant extract treatment. At
Anti-Cancer Activity of Buxus Plant Extracts
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(Figure S6), this can be explained by the fact that the cell line did
not undergo mitosis and can hence explain the disappearance of
Survivin.
It is known that the up-regulation of Survivin expression in
cancer cells is independent of the cell cycle, suggesting an increase
of its anti-apoptotic role compared to normal cells, in which its
mitotic regulation functions may be predominant.
Beclin 1 is a 60-kDa protein that plays a critical role in the
formation of auto-phagosomes in mammalian cells [38,39]. 40%
of human breast carcinoma cell lines exhibit deletions of one or
more alleles of beclin 1 gene [40]. This decreased expression of
Beclin 1 suggests that specific molecular alterations in autophagy
pathways may contribute to tumorigenesis [41]. As illustrated in
Figure 4, 6B and 6C, an increase in Beclin 1 levels was noticed in
treated MCF7, T47D and BT-20, respectively, demonstrating that
the plant extract triggers autophagic cell death.
Acetonic Buxus extract induces apoptosis in T47D and
BT-20
Since we have noticed the presence of pre-apoptotic subpop-
ulations in Annexin V-FITC stained cells, we decided to check the
occurrence of apoptosis in these cell lines. As illustrated in
Figure 6B and 6C for T47D and BT-20, respectively, after 3 h of
treatment, there is occurrence of apoptosis since there is expression
of certain apoptosis markers : caspase 3, cH2AX. In parallel,
autophagy occurs in these cells, since there is a concomitant
overexpression of Beclin-1 (Figure 6B and 6C).
Discussion
In this study, we report cytotoxic effects of a plant extract –
acetonic extract of Buxus sempervirens L. – on several breast cancer
cell lines. Cytotoxic activities concerning Buxus species are scarce;
although an interesting cytotoxic activity is reported for triterpe-
noid alkaloids isolated from Buxus microphylla L. against HepG2
[28]. According to our results, in breast cancer cell lines, the Buxus
acetonic extract induced cell cycle arrest in G0/G1 phase and
triggered cell death by increased sub-G1 cell population. The
observed effects could be mediated by two sub-classes of cytotoxic
molecules, a first class could act fast and require high
concentration to induce cell death, and a second class plays a
role in cell cycle arrest by preventing the G1-to-S transition.
Alternatively, all these effects could be attributed to a single
molecule. This conclusion arises from previous similar results
described in the literature with Resveratrol [42]. Indeed, this
phytoalexin stilben isolated from grapes, wine and nuts, induces
cell cycle arrest at low concentrations and cell death through
Figure 3. Buxus extract induces autophagy in cancer cells as evidenced by PI/Annexin V double staining and FACS analysis. A–B. PI/
Annexin V double staining of untreated and treated MCF7 (A) and MCF10CA1a (B) cells with IC50 concentration for 24 h and 48 h. C. FACS analysis
with PI/Annexin V double staining of MCF10A cell line (control cell line) treated with MCF7 and MCF10CA1a IC50 respective Buxus extract
concentrations for 24 h and 48 h.
doi:10.1371/journal.pone.0024537.g003
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concentrations [42]. This is a very striking finding, since our
preliminary results revealed the absence of Resveratrol in Buxus
extracts. Also, it is worthy to notice that the plant was collected in
an area characterized by unfavorable growth conditions (moun-
tainous and semi-arid region) which are known to trigger the
production of phytoalexin substances.
Our investigation concerning cell cycle arrest revealed also a
highly sought characteristic. The Buxus acetonic extract is able to
block cell cycle in G0/G1 through the decrease in cyclin D1.
Cyclin D1 belongs to the family of three closely related D-type
cyclins, D1, D2 and D3, which are redundant in all proliferating
cell types. D-cyclins together drive cell-cycle progression by
activating their cyclin-dependent kinase partners, CDK4 and
CDK6, which leads to phosphorylation of the retinoblastoma
protein (Rb), and in turn to the advance through the G1 phase of
the cell cycle [43,44]. Cyclin D1 is over-expressed in most breast
tumor cell lines through over-expression and/or amplification at
its genomic locus, 11q13. This feature has been shown to play a
key role in tumorigenesis and confers bad prognosis in breast
cancer [45–47]. Moreover, the cell cycle arrest observed cannot be
the result of CDK inhibitors activation as shown by decreased
levels of p21 and p27 (data not shown). Rather, the effect relies on
a direct decrease in cyclin D1, strongly suggesting that inhibition
of cyclin D1 by Buxus extract could be a good tool to improve
prognosis in breast cancer.
Another interesting feature concerns the concomitant occur-
rence of the two programmed cell deaths, apoptosis and
autophagy, in several breast cancer cells including triple positive
and triple negative ones, since our results have shown markers
related to both of them. Transmission electron microscopy
analyses showed marked differences in localization and shapes of
mitochondria in Buxus extract-treated MCF10CA1a cells. The
cellular distribution of mitochondria is deeply affected during
apoptosis. Mitochondria are normally dispersed throughout the
entire cell; however, during apoptosis triggered by tumor necrosis
factor (TNF), there is a peri-nuclear clustering of mitochondria is
caused by an impaired activity of the molecular motor kinesin
[48]. Also, the loss of integrity of the mitochondria outer
membrane is a very important hallmark of apoptosis. Referred as
MOMP (Mitochondrial Outer Membrane Permeabilization), it
leads to the release of proteins normally found in the space
between the inner and outer mitochondrial membranes, such as
cytochrome C and AIF (Apoptosis Inducing Factor) [49]. It is
well established that the release of these molecules initiates
apoptosis. Cytochrome C binds to APAF-1 (apoptotic protease
activating factor–1). In the presence of ATP, APAF-1 is allowed
to oligomerization and forms the ‘‘apoptosome’’ which, in turn,
activates Caspase 9 by dimerization. The active Caspase 9
activates executor caspases (Caspase 3 and 7) and this
orchestrates apoptosis through the cleavage of key substrates
within the cell [50]. Also, AIF has a direct effect on isolated
nuclei, triggering chromatin condensation as well as large-scale
chromatin fragmentation [51].
Figure 4. Acetonic extract of Buxus induces autophagy in MCF7
cell line. A. Transmission electron microscopy pictures of untreated
and Buxus extract-treated MCF7 cells with IC50 concentration for 72 h.
Black arrows show degradative autophagic vesicles. White arrows show
lucent electron vesicles. B. Immunoblots of total cell extracts isolated
from MCF7 (treated and untreated, as indicated) probed with different
antibodies demonstrating the occurrence of autophagy. b-actin has
been used as a loading control. C. Immunofluorescence targeting LC3
obtained with untreated and Buxus extract-treated MCF7 cells (IC50,
72 h). Magnification 6400. Ac Bux: acetonic Buxus extract.
doi:10.1371/journal.pone.0024537.g004
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mechanism of cell survival following plethora of extra-cellular
and intra-cellular stimuli. Numerous studies have demonstrated
that proceeding to autophagy allows cancer cells to escape cell
death [52–55]. Nevertheless, the autophagy is highly contextual, it
can exert both cyto-protective and death-promoting effects.
Indeed, the effect of autophagy may vary dependent on the type
of cancer, individual characteristics of cancer cells, microenviron-
ments, and therapeutic treatment [52]. Nonetheless, it is clearly
assumed that induction of autophagy to high levels leads to
autophagic cell death [56,57].
Interestingly, the Buxus extract induced a decrease in p21 levels,
which could be related to its involvement as an anti-apoptotic
protein. This is exemplified by preventing apoptosis by protecting
the N-terminal moiety of Caspase 3 preventing its activating
proteolysis [58]. Lately, p21 has been reported to play a crucial
role in autophagy [59]; although, the entire mechanism is not fully
understood. Wild-type MEF (Mouse Embryonic Fibroblasts)
undergo apoptosis upon C2-ceramide treatment, and p21
2/2
MEF undergo autophagy rather than apoptosis upon the same
death stimulus. p21 triggers apoptosis by inhibiting the autophagic
pathway through the suppression of the stability of autophagy-
related proteins in MEF [59]. Hence, decreased levels of p21
observed in the cells treated with the plant extract can trigger cell
death by autophagy.
By decreasing levels of p21, the Buxus extract seems to contain
molecules that inhibit cytosolic p21 and trigger cell death. It has
been already shown that targeting p21 (with an anti-sense
oligodeoxynucleotide) attenuated the growth of Met-1 tumors in
nude mice [60]. Finally, our data demonstrated that the Buxus
extract also decreases levels of Survivin, a 16.5 kDa protein that
belongs to the IAP family (Inhibitor of Apoptosis proteins) [61],
which plays a key role in mitotic spindle formation [62]. However,
two general considerations make Survivin an attractive therapeutic
target in cancer: it is selectively expressed in tumor cells and it is
required for their viability [63,64]. In cancer cells, Survivin
correlates with unfavorable prognosis, resistance to therapy, and
accelerated rates of recurrences [65].
In light of our results, we can conclude that Buxus sempervirens
extract targets many proteins widespread in cancer cells
cytoplasm, leading to cell cycle arrest and autophagy. There is
however a crosstalk between apoptosis and autophagy, which
determines cell fate, but the molecular mechanism is not fully
understood. Previous data suggested that the removal or functional
inhibition of essential proteins from the apoptotic machinery can
switch a cellular stress response from the apoptotic default
pathway to a state of massively increased autophagy. However,
apoptosis develops only when autophagy is inhibited [66]. In our
case, mechanisms of the concomitant occurrence of autophagy
and apoptosis are unclear. A possible explanation for the
autophagy observed in MCF10CA1a cells can be the presence
of Ha-Ras. This aggressive cell line was obtained by transfecting
MCF10A with this oncogene. It has been lately shown that the
presence of this signature leads to the occurrence of autophagy
[67].
Figure 5. Acetonic extract of Buxus induces autophagy in
MCF10CA1a cell line. A. Transmission electron microscopy pictures
of untreated and Buxus extract-treated MCF10CA1a cells (IC50, 72 h).
Black arrows show degradative autophagic vesicles. White arrows show
damaged mitochondria. B. Immunoblots of total cell extracts isolated
from MCF10CA1a (treated and untreated, as indicated) probed with
different antibodies demonstrating the occurrence of autophagy. b-
actin has been used as a loading control. C. Immunofluorescence
targeting LC3 obtained with untreated and treated MCF10CA1a cells
(IC50, 72 h). Magnification 6400. Ac Bux: acetonic Buxus extract.
doi:10.1371/journal.pone.0024537.g005
Anti-Cancer Activity of Buxus Plant Extracts
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24537Conclusion
Nowadays, it is accepted that the major problem with
conventional chemotherapy lies in the doses used: low doses have
no effect on cancer cells and too high doses induce deleterious side
effects. Thus, the presence of a ‘‘sensitizer’’ that can force cells to
undergo apoptosis even with mild DNA-damaging agents would
greatly enhance the efficacy and limit side effects of conventional
chemotherapy drugs [68]. Hence, targeting p21 and Survivin can
be a good adjuvant therapy to improve cell death in accompa-
niment to other conventional drugs [69,70]. Buxus extract
probably contains molecules that inhibit p21 and Survivin and
thus can be used in addition to commonly used drugs to trigger cell
death.
Another important feature concerning Buxus extract is its
capacity to target the cell cycle which is very promising in cancer
chemotherapy. Agents that induce cell cycle arrest are increasingly
used in combination with traditional cytotoxic drugs to overcome
cell cycle–mediated drug resistance and to improve cytotoxic
efficacy. Among them, Flavopiridol has been shown to directly
inhibit many CDK proteins [71].
Taken together, our data suggest that Buxus sempervirens extract
can induce cell death not only via apoptosis, but also by
autophagy. This is very promising, since it indicates that the
Buxus extract may contain molecules that can be potentially used
in apoptosis-resistant cells. Also, it exhibited increased toxicity
towards cancer cell lines, including triple negative breast cancer
cells. Moreover, it induced cell cycle arrest, depletion of cell
energy, leading to cell death. Finally, Buxus deserves further
investigation to understand the potential use of its molecules in
therapeutic application for cancer treatment.
Materials and Methods
Plant extract preparation
Buxus sempervirens L. (Buxaceae) was collected from remote places
around the province of Be ´jaia (with the kind permission of the
Parc National de Dujurdjura authorities, Northeastern region of
Algeria) in March 2008. Plant parts (leaves and flowers) used in
this study were chosen on the basis of their use in Algerian
ancestral medicine.
Powdered material (2 g) was macerated in pure acetone
(200 ml) during 24 h, at room temperature with light stirring
(50 rpm), and then filtered using 0.22 mm filters (Millipore). The
flow-through material was evaporated to dryness under reduced
pressure and the solid extract was reconstituted in DMSO solvent
(100 mg/ml stock solution) before storage at 220uC.
Cell culture
MCF7 cells (HTB-22, ATCC) were grown in Dulbecco’s
Modified Eagle Medium (DMEM), 4.5 g/l of glucose, supple-
mented with 5% fetal calf serum, 100 U/mL of penicillin (PAA),
and 100 mg/mL of streptomycin (PAA). MCF10A cells (CRL-
10317, ATCC) were cultured in DMEM/F-12 medium (PAA,
Carlsbad, CA) supplemented with 10 mg/mL of human insulin
(Sigma, St. Louis, MO), 20 ng/mL of epidermal growth factor
(Sigma, St. Louis, MO), 0.5 mg/mL of hydrocortisone (Sigma, St.
Louis, MO), 5% horse serum (Invitrogen), 100 U/mL of penicillin
(PAA) and 100 mg/mL of streptomycin (PAA). T47D (HTB-133,
ATCC), a generous gift from Dr Yegor Vassetzky were grown in
DMEM, 4.5 g/l of glucose, supplemented with 10% horse serum,
100 U/mL of penicillin (PAA), and 100 mg/mL of streptomycin
(PAA). BT-20 (HTB-20, ATCC) and MDA-MB-435 cells (HTB-
129, ATCC) were cultured in DMEM, 4.5 g/l of glucose,
supplemented with 10% fetal calf serum, 100 U/mL of penicillin
(PAA), and 100 mg/mL of streptomycin (PAA). MCF10CA1a cells
[72] were cultured in DMEM/F-12 medium supplemented with
5% fetal calf serum (PAA), 100 U/mL of penicillin (PAA) and
100 mg/mL of streptomycin (PAA). All cited cells were cultured at
37uC in a humidified atmosphere and 5% CO2.
Viability assay
Cell proliferation was determined using the Cell Titer Glo assay
(Promega). Cells were seeded at a density of 3610
3 cells per well in
96-well plates and maintained 24 h for attachment and then
treated with two-fold serial dilutions of the plant extract. After
72 h incubation, 20 mL of MTT reagent were added. The plates
were incubated during 2 h and absorbance determined at 560 nm
in Glomax Multi-detection System (Promega). Percentages of cell
survival were calculated as follows: % cell survival=(absorbance of
treated cells/ absorbance of cells with vehicle solvent)6100. The
Figure 6. Buxus extract induces apoptosis in MCF10CA1a, T47D
and BT-20 breast cancer cell lines. A. Immunoblots of total extracts
from MCF10CA1a, revealing the presence of the cleaved from of PARP
and cH2AX, hall marks of apoptosis, at the same time, the blot reveals
the absence of active caspase 3, demonstrating the occurrence of
apoptosis without caspase 3 activation. B. and C. Immunoblots of total
extracts from T47D and BT-20, respectively, revealing the presence of
the cleaved from of caspase 3 and cH2AX, hallmarks of apoptosis,
demonstrating the occurrence of apoptosis and an up-regulation of
Beclin-1, proving the occurrence of autophagy at the same time.
GAPDH was used as a loading control. Ac Bux: acetonic Buxus extract.
doi:10.1371/journal.pone.0024537.g006
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response curve obtained by plotting the percentage of cell survival
versus the concentration of plant extract used. All assays were
performed three times in duplicate. During all experiments,
DMSO dilutions of Buxus acetonic extract were adjusted in the
culture media at a final concentration of 0.2% (v/v).
FACS analysis, PI and PI/Annexin V staining
In order to determine the effect of plant extract on the cell cycle,
FACS analysis was carried out. For propidium iodide (PI) staining,
cells were seeded in 6-well plates at a density of 10
4 cells/ml. After
24 h of attachment, cancer cells were treated with indicated plant
extract concentrations for different time intervals. Floating and
attached cells were harvested, washed in PBS, fixed in ice-cold
ethanol (70% v/v) and stored at 220uC. For analysis, cells were
washed in PBS and suspended in PI (25 mg/ml) in PBS with
RNase A (200 mg/ml).
For PI/Annexin V double staining, treated cells were harvested
and suspended in binding buffer (HEPES pH 7.4, CaCl2 2.5 mM,
NaCl 140 mM). Aliquots of cells were incubated for 15 mn with
Annexin V FITC and PI (5 mg/mL) (Invitrogen).
During all FACS analyses, 10
5 events for each sample were
analyzed. Flow cytometry analyses were carried out on a
FACScalibur system (BD Biosciences) followed by analysis using
CellQuest Pro software (BD Biosciences).
Ultra-structural study by transmission electronic
microscopy
Treated (IC50/72 h) and control cells were fixed in buffered
(0.1 M) sodium cacodylate, pH 7.4 and 2.5% glutaraldehyde
solution for 2 h. After washing, the cells were post-fixed in 1%
OsO4 solution for 1 h at room temperature, rinsed and
dehydrated in an ethanol gradient (70% to 100%, 10 min for
each bath). Absolute ethanol was replaced by 2,3 epoxy
propylether and further by propylene oxide. Cells were infiltrated
by epoxy resin (R1165, Agar scientific) mixed to propylene oxide
(50%-50%) overnight, followed by three baths with pure epoxy
resin. Samples were polymerized at 60uC during 18 h. Ultra-thin
sections (80 nm) cut with an ultra-microtome (Leica UC6) were
stained with uranyl acetate (20 min) and Reynolds lead citrate
(2 min). Sections were observed at 80 kV, in a TEM Phillips
Tecnai equipped with an Olympus Keenview CCD camera.
Immunofluorescence
Cells were grown on Permanox slides during 24 h before Buxus
acetonic extract treatment (IC50, 72 h). They were fixed with a
paraformaldehyde solution (4%) and permeabilized with 0.1%
Triton X-100 in PBS, before incubation with appropriate
antibodies: a-tubulin (1/5000, Sigma), LC3 (1/200, Sigma)
overnight at 4uC. After extensive washing, slides were incubated
1 h at room temperature with red fluorescent Alexa Fluor 568
dye-labeled anti-mouse IgG for a-tubulin and green-fluorescent
Alexa Fluor 488 dye-labeled anti-rabbit for LC3. Coverslips were
mounted in DAPI (49,6-diamidinole-2-phenolindole) (Sigma
Aldrich). Finally, cells were observed with a Leica DMI 6000 B
microscope and images were treated with MetaMorph software.
Western blot
Cell extracts were prepared in RIPA (50 mM Tris-HCl
(pH 7.5), 150 mM NaCl, 1% NP40, 0.5% Na-deoxycholate,
0.1% SDS, 1 mM EDTA containing protease inhibitor mixture
(Roche Applied Science). After sonication on a Bioruptor
(Diagenode) at high frequency during 7.5 mn (1 mn of pause
versus 15 sec of sonication), the soluble protein fraction was
collected after centrifugation at 13 500 g during 10 mn. Protein
concentration was determined BCA kit according to manufactur-
er’s instructions (Pierce, Rockford, IL). 30 mg of proteins were
subjected to SDS-PAGE in 4 to 12% gradient gels and separated
proteins were transferred to nitrocellulose membrane (Invitrogen).
Incubation with different antibodies was monitored overnight at
4uC. Membranes were incubated with the appropriate secondary
antibody coupled to HRP (Horseradish Peroxidase), revealed
using West Dura kit (Pierce, Rockford, USA) and ChemiSmart
5000 system (Vilber Lourmat).
Antibodies
The antibodies against p21 (C-19, sc-397), cyclin A2 (C-19, sc-
596), cyclin D1 (DCS-6, sc-20044), cyclin D3 (C-16, sc-182),
cyclin E1 (E-4, sc-25303), Rb (C-15, sc-50) were from Santa
Cruz Technologies. Anti-cleaved caspase 3 (Asp 175 9661) was
purchased from Cell Signaling Technologies. Anti-PARP (33–
3100) was from Zymed Inc, anti-LC3 (L8918). Antibodies against
Beclin-1 (B6061), b-actin (T9026), a-tubulin (A5441) and GAPDH
(G8795), normal mouse and normal rabbit IgG were from Sigma
Aldrich. Anti-Survivin (Ab469) was from Abcam.
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Supporting Information
Figure S1 Dose effect of the acetonic extract of Buxus on
MCF7 cells. A. FACS analysis of treated MCF7 with increasing
concentrations of Buxus extract. The results are the mean 6 SEM
of three experiments. The results demonstrate a dose effect with
increased sub-G1 subpopulation upon plant extract treatment. B.
Immunoblot analyses of total extract of treated MCF7 cells treated
with increasing concentrations of Buxus showing the multiple
targets of the extract at high concentrations. GAPDH was used as
a loading control.
(EPS)
Figure S2 Dose effect of the acetonic extract of Buxus on
MCF10CA1a cells. A. FACS analysis of treated MCF10CA1a
with increasing concentrations of Buxus extract. The results
represent means 6 SEM of three experiments. The results
demonstrate a dose effect with increased Sub-G1 subpopulation
upon plant extract treatment. B. Immunoblot of total extract of
treated MCF10CA1a cells treated with increasing concentrations
of Buxus showing the multiple targets of the extract at high
concentrations. GAPDH was used as a loading control.
(EPS)
Figure S3 Treatment of T47D (an aggressive triple
positive breast cancer cell line) and BT-20 (a triple
negative brast cancer cell line) cells with Bux acetonic
extracts resulted in the accumulation of cells in G0/G1
phase in a dose- and time-dependent fashion. A. and D.
T47D and BT-20, respectively, were treated in increasing
concentrations of the plant extract (IC50/2, IC50 and 26IC50)
during 24 h and 48 h and resulted in an accumulation of cells in
G0/G1 phase as demonstrated by FACS analyses. The results
represent means 6 SEM of three experiments. B and E. Western
blots analysis of untreated and treated T47D and BT-20 cells,
respectively, showing a decrease of cyclin D1 after their respective
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and F. Western blot analysis of total cell extracts from untreated
and treated T47D and BT-20 cells, respectively, with increasing
concentrations of Ac Bux (IC50/2, IC50 and 26 IC50) during
48 h, illustrating a dose effect of Ac Bux on the several targeted
proteins probed. Ac Bux: acetonic Buxus extract.
(EPS)
Figure S4 Treatment of T47D and BT-20 cells with the
plant extract resulted in the accumulation of apoptotic/
necrotic cells. A. T47D cells were treated during 24 h and 48 h
with the plant extract (IC50) and resulted in the accumulation of
apoptotic/necrotic cells as illustrated with the Annexin V-FITC
stained cells analyzed by FACS. B. Annexin V-FITC stained BT-
20 cells showing that after 24 h of plant extract treatment (IC50),
there is an emergence of pre-apoptotic cells that shift to apoptotic/
necrotic cell population after 48 h of treatment.
(EPS)
Figure S5 Buxus extract treatment in T47D and BT-20
cells resulted in autophagy. A and C. Immunofluorescence
targeting LC3 obtained with untreated and treated T47D and BT-
20 cells, respectively, (IC50, 72 h), showing the punctuated staining
of the processed form LC3 II. Magnification 6400. Ac Bux:
acetonic Buxus extract. B and D. Immunoblots of total cell
extracts of untreated and treated T47D and BT-20 cells,
respectively, (IC50 during 24 h and 48 h) demonstrating the
occurrence of the processed form of LC3 and the decrease of p21
levels.
(EPS)
Figure S6 Immunoblot analysis of total cell extracts
isolated from MCF10A demonstrating the absence of the
processed LC3II and caspase 3 in treated cells. Only a
small band related to LC3II is present when cells were treated with
MCF7-IC50. a-tubulin was used as a loading control.
(EPS)
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